Sharekhan

#SharekhanResearch retains Buy on #LaurusLabs (12month PT Rs735) #FY22 Annual report point to robust growth outlook… https://t.co/MIeyS4wI8I #SharekhanResearch #LaurusLabs #FY22

#SharekhanFNA #SharekhanResearch retains Buy on #LaurusLabs (PT Rs735) #Q3FY22 was a weak qtr, results missed est;… https://t.co/5FLSMtWLVJ #SharekhanFNA #SharekhanResearch #LaurusLabs #Q3FY22

#SharekhanResearch retains Buy on #LaurusLabs (PT Rs735);DCGI emergency nod for #Molnupiravir & #ImmunoACT stake ac… https://t.co/mjrAEYGQOX #SharekhanResearch #LaurusLabs #Molnupiravir #ImmunoACT

#SharekhanResearch reiterates Buy on #Lauruslabs(PT Rs 800), clarification on non- suspension of marketing approval… https://t.co/KpQxNZAROV #SharekhanResearch #Lauruslabs

#SharekhanResearch retains Buy rating on #LaurusLabs (PT Rs800); reports strong results for #Q1FY22; robust growth… https://t.co/oj2pOjUfj5 #SharekhanResearch #LaurusLabs #Q1FY22

#SharekhanResearch retains Buy rating on #Lauruslabs (PT Rs750) FY21 annual report emphasises on sustainable growth… https://t.co/gWH0NwKck6 #SharekhanResearch #Lauruslabs

#SharekhanFNA #SharekhanResearch retains Buy rating on #Lauruslabs (PT Rs 550) #Q4FY21 was a strong quarter; basis… https://t.co/NicGeBPziq #SharekhanFNA #SharekhanResearch #Lauruslabs #Q4FY21

#sharekhanFNA #Sharekhanresearch retains Buy on #Lauruslabs (PT Rs450); expect robust growth outlook across segment… https://t.co/8ttCd0HokG #sharekhanFNA #Sharekhanresearch #Lauruslabs

#SharekhanFNA #SharekhanResearch retains buy recommendation on #LaurusLabs (PT Rs410); Strong growth prospects for… https://t.co/6u7oyGKGTH #SharekhanFNA #SharekhanResearch #LaurusLabs